Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases
Bain Capital and Cinven, the owners of Lonza Specialty Ingredients (LSI), are among parties conducting early work on Bayer's carve-out of its Environmental Science Professional (ESP) division, according to sources familiar with the matter.
Britain’s SMEs have been thrown off course by the coronavirus crisis. Here, Bill Nixon explains how his Glasgow-based Maven Capital is enabling them to get back on track.
Recent Comments